Related Experiment Videos
A "malignant" variant of status epilepticus
Martin Holtkamp1, Jalal Othman, Katharina Buchheim
1Department of Neurology, Charité -- Universitätsmedizin Berlin, Auguste-Viktoria-Krankenhaus Berlin, Germany. martin.holtkamp@charite.de
Archives of Neurology
|September 15, 2005
Summary
Malignant status epilepticus (SE) affects 20% of patients unresponsive to initial treatments. Young patients with encephalitis are at higher risk, necessitating aggressive early intervention for better outcomes in refractory epilepsy.
Area of Science:
- Neurology
- Critical Care Medicine
Background:
- Status epilepticus (SE) often resists first-line anticonvulsants, necessitating anesthetic agents.
- A subset of SE cases remains intractable even with anesthetics, termed malignant SE.
- Malignant SE represents the most severe and refractory form of status epilepticus.
Purpose of the Study:
- To determine the incidence of malignant SE.
- To identify risk factors associated with malignant SE.
- To evaluate the in-hospital outcomes for patients experiencing malignant SE.
Main Methods:
- Retrospective cohort study design.
- Analysis of 35 SE episodes in 34 patients admitted to a neurological intensive care unit.
- Comparison of predictive and prognostic features between malignant SE and other refractory SE cases.
Main Results:
- Malignant SE occurred in 20% of cases refractory to first-line anticonvulsants.
- Younger patient age and encephalitis were significant risk factors for malignant SE.
- Malignant SE was associated with prolonged seizure activity, extended ICU and hospital stays, and increased functional dependency at discharge.
Conclusions:
- Malignant SE is a significant complication following first-line anticonvulsant failure.
- Young patients, particularly those with encephalitis, are at increased risk.
- Early aggressive treatment is recommended for patients at risk to prevent malignant SE progression.